# Cerebrolysin

Pig-brain peptide mix for stroke/TBI; strong anecdotes, real safety questions.

- Page: https://peprank.xyz/peptides/cerebrolysin
- Category: Neuroprotection & repair (Research peptide)
- Also known as: FPF-1070; porcine brain-derived peptide preparation
- Routes: Nasal / Injection / IV
- Safety tier: Strict: Avoid · Balanced: Avoid · Evidence only: Avoid
- Risk axes (0 none to 3 severe): Seen harm 2, Mechanism 2, Data gap 1, Silent harm 1, Product 3
- Positive: 40% of 29 graded reports glowing or positive, shrunk toward the 49% all-report average by 8 reports' weight
- Rank: #55 of 61 research peptides
- Graded reports: 29 (Glowing 6, Positive 5, Mixed 3, Nothing 5, Negative 5, Bad reaction 5)
- Evidence: Approved drug — in roughly 40+ countries, mainly Eastern Europe and Asia (not US/UK); human RCTs (stroke), mixed
- Access: Approved drug
- Onset: Some feel calm, sleepiness or a mood lift after the first injection; most say benefits build over 1-3 weeks of daily dosing. Brain fog and fatigue in the first days, or a slump in week 2, are common.
- Lasts: Cumulative rather than per-dose: users report benefits lasting weeks to a few months after a 4-week course, then fading.
- Cost per month: ≈ €140–540 (researchers' estimate)
- Updated: 2026-10-30

**Why Avoid under the strict bar:** Cochrane found more non-fatal serious adverse events than placebo; animal-derived injectable with allergy/immune reaction risk.

## What users report

Strong anecdotes, especially from TBI, long-COVID and stutter users (sleep, recall, mood, anxiety), with cycle-and-repeat loyalty. Perhaps 25-35% notice nothing after a full cycle, a recurring group feels much worse for 1-3 weeks mid-cycle, and there are a few alarming threads (persistent dysautonomia, small-fibre neuropathy) after injection or nasal use.

**Effects:** better sleep; recall and word-finding after brain injury; reduced anxiety/panic; mood lift

**Downsides:** IM injection pain, light-headedness; mid-cycle fog/fatigue/emotional lows; cost and sourcing (counterfeits; only EVER Pharma considered genuine)

**Risks:** Cochrane 2023 (7 RCTs, 1773 pts): more non-fatal serious adverse events than placebo, RR 2.39 (95% CI 1.10-5.23), moderate certainty; animal-derived protein mix: anaphylaxis/allergy; labelled contraindications include epilepsy and severe renal impairment; anecdotal autoimmune-type reactions (neuropathy, persistent dysautonomia), especially after nasal use

**Typical use:** 5-10 mL IM daily, 5 on/2 off for 4 weeks (community); higher IV doses clinically.

**Getting it:** Pharmacy drug in Austria, Eastern Europe, Russia, Asia and Latin America (sold as Renacenz in Mexico); not approved in the US or UK, where people import it from online pharmacies or buy from a few US compounding pharmacies. Chinese 'cerebroprotein hydrolysate' vials are a different, unverified product.

**Stacked with:** Cortexin (Often run together (Cerebrolysin used to reconstitute the Cortexin vial) or rotated between courses.); Semax or Selank (Common companions in TBI and anxiety protocols; one user found Cerebrolysin removed Semax's insomnia.); Growth hormone (Some heavy users claim synergy; GH lethargy plus Cerebrolysin brain fog was described as brutal at higher doses.); Stimulants and dopaminergic drugs (Users report it raises sensitivity to stimulants and nicotine, so doses that were normal before can feel too strong.)

## Risk profile

- **Seen harm 2/3:** A trial SAE signal: Cochrane (7 RCTs, 1,773 patients) found more non-fatal serious adverse events than placebo (RR 2.39, 95% CI 1.10-5.23, moderate certainty). Its label lists very rare shock-like reactions, a lab-confirmed life-threatening anaphylaxis was published in 2024, and several first-hand reports describe small-fibre neuropathy lasting months, including from genuine pharmacy product; no death is reliably attributed.
- **Mechanism 2/3:** An undefined mix of porcine brain peptides given by injection: immune and allergic activation is credible, and the label warns that seizure frequency may rise in epilepsy.
- **Data gap 1/3:** Approved in Austria, Russia and many other countries for decades, with RCTs totalling 1,773 stroke patients, but not approved by EMA centrally or FDA.
- **Silent harm 1/3:** Anaphylaxis and infusion reactions are immediate; the neuropathy reports began within days but persisted for months.
- **Product 3/3:** Injected ampoules bought from export pharmacies or compounders, with counterfeits reported; some users improvise nasal use.
- **Never if:** Epilepsy, especially status epilepticus (label); Severe kidney impairment (label); Allergy to porcine proteins; Pregnancy or breastfeeding (no human reproductive data)

## Top reports

- Glowing, mood, 5 mL/day, 5 on/2 off: “The most surprising effect was my lifelong stuttering improving massively around weeks 3-4. At times I felt 90% more fluent than my normal baseline” — [r/Cerebrolysin](https://www.reddit.com/r/Cerebrolysin/comments/1wmbnig/i_took_cerebrolysin_for_4_weeks_my_lifelong/)
- Glowing, neuroprotection: “Yes, massive difference when using it to recover from alpha covid cognitive issues.” — [r/Cerebrolysin](https://www.reddit.com/r/Cerebrolysin/comments/1v8sule/has_anyone_here_actually_felt_a_noticeable/p09czbp/)
- Glowing, sleep: “I have had insomnia for years and have tried everything known to man…natural supplements, OTC, even prescription meds and nothing has helped. Just did my first cycle of Cerebrolysin (20 days 5mg) and my sleep scores are awesome now with 7-8 hrs!” — [r/Cerebrolysin](https://www.reddit.com/r/Cerebrolysin/comments/1v8sule/has_anyone_here_actually_felt_a_noticeable/p0abs01/)
- Glowing, focus: “A huge difference but I have a brain injury so it was absolutely noticeable for me with recall and depression” — [r/Cerebrolysin](https://www.reddit.com/r/Cerebrolysin/comments/1v8sule/has_anyone_here_actually_felt_a_noticeable/p0af8v8/)
- Glowing, mood: “I used Cerebrolysin to treat my panic disorder and by some miracle it eradicated most of it. I was having multiple panic attacks a day for around 3 months (sudden onset OCD, GAD, panic disorder when I was 21), and after the first Cerebrolysin injection I haven’t had another one.” — [r/Cerebrolysin](https://www.reddit.com/r/Cerebrolysin/comments/1v8sule/has_anyone_here_actually_felt_a_noticeable/p0f5i7x/)

## Cheapest in Europe

- [Europa-Peptide](https://europa-peptide.de/en/shop/cerebrolysin-60mg/) (PL): Cerebrolysin 60mg (lyophilised vial), €63, €1.05/mg
- [EuropeChemist](https://europechemist.com/product/cerebrolysin/) (NL): Cerebrolysin 5 ml, 5 ampoules/pack, €110

## Studies

- [Ziganshina et al. 2023 (Cochrane): Cerebrolysin for acute ischaemic stroke](https://pubmed.ncbi.nlm.nih.gov/37818733/) (meta-analysis, n=1773, 2023): Seven RCTs (six Cerebrolysin, one Cortexin) showed little to no difference in all-cause death (RR 0.96) and more non-fatal serious adverse events than placebo; moderate-certainty evidence.
- [Heiss et al. 2012: Cerebrolysin in acute ischemic stroke in Asia (CASTA)](https://pubmed.ncbi.nlm.nih.gov/22282884/) (rct, n=1070, 2012): 30 mL IV daily for 10 days did not beat placebo on the combined primary endpoint; a post hoc trend favoured it only in severe strokes (NIHSS > 12).
- [Muresanu et al. 2016: Cerebrolysin and Recovery After Stroke (CARS)](https://pubmed.ncbi.nlm.nih.gov/26564102/) (rct, n=208, 2016): Large benefit on arm function (Action Research Arm Test) at day 90 in early rehabilitation, safety comparable to placebo; exploratory and manufacturer-linked.
- [Gauthier et al. 2015: Cerebrolysin in mild-to-moderate Alzheimer's disease, meta-analysis of 6 RCTs](https://pubmed.ncbi.nlm.nih.gov/25832905/) (meta-analysis, 2015): Better cognition at 4 weeks (not significant at 6 months) and better global clinical change at 4 weeks and 6 months versus placebo; analysis run with the manufacturer's statisticians.
- [Verisezan Rosu et al. 2023: Cerebrolysin and rTMS after traumatic brain injury, three-arm RCT](https://pubmed.ncbi.nlm.nih.gov/37360156/) (rct, n=93, 2023): Safe and well tolerated, but no statistically significant difference on the primary cognitive outcomes at 3 and 6 months.

## Sources

- [Cochrane 2023: Cerebrolysin for acute ischaemic stroke](https://pubmed.ncbi.nlm.nih.gov/37818733/)
- [Cochrane plain-language summary](https://www.cochrane.org/evidence/CD007026_cerebrolysin-acute-ischaemic-stroke)